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Abstract
Background: Perinatal asphyxia and resulting hypoxic-ischemic encephalopathy is a major cause of death and long-
term disability in term born neonates. Up to 20,000 infants each year are affected by HIE in Europe and even more in
regions with lower level of perinatal care. The only established therapy to improve outcome in these infants is
therapeutic hypothermia. Allopurinol is a xanthine oxidase inhibitor that reduces the production of oxygen radicals as
superoxide, which contributes to secondary energy failure and apoptosis in neurons and glial cells after reperfusion of
hypoxic brain tissue and may further improve outcome if administered in addition to therapeutic hypothermia.
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Methods: This study on the effects of ALlopurinol in addition to hypothermia treatment for hypoxic-ischemic Brain
Injury on Neurocognitive Outcome (ALBINO), is a European double-blinded randomized placebo-controlled parallel
group multicenter trial (Phase III) to evaluate the effect of postnatal allopurinol administered in addition to standard of
care (including therapeutic hypothermia if indicated) on the incidence of death and severe neurodevelopmental
impairment at 24months of age in newborns with perinatal hypoxic-ischemic insult and signs of potentially evolving
encephalopathy. Allopurinol or placebo will be given in addition to therapeutic hypothermia (where indicated) to infants
with a gestational age≥ 36 weeks and a birth weight≥ 2500 g, with severe perinatal asphyxia and potentially evolving
encephalopathy. The primary endpoint of this study will be death or severe neurodevelopmental impairment versus
survival without severe neurodevelopmental impairment at the age of two years. Effects on brain injury by magnetic
resonance imaging and cerebral ultrasound, electric brain activity, concentrations of peroxidation products and S100B,
will also be studied along with effects on heart function and pharmacokinetics of allopurinol after iv-infusion.
Discussion: This trial will provide data to assess the efficacy and safety of early postnatal allopurinol in term infants
with evolving hypoxic-ischemic encephalopathy. If proven efficacious and safe, allopurinol could become part of a
neuroprotective pharmacological treatment strategy in addition to therapeutic hypothermia in children with perinatal
asphyxia.
Trial registration: NCT03162653, www.ClinicalTrials.gov, May 22, 2017.
Keywords: Allopurinol, Neonatal oxygen deficiency, Hypothermia therapy, Childbirth outcome, Hypoxic-ischemic
encephalopathy, Perinatal asphyxia, Brain injury, Cerebral palsy
Background
Neonatal hypoxic-ischemic encephalopathy (HIE) as a
result of perinatal asphyxia is a major cause of death and
long-term disability in term neonates. About 1–4 per
1000 live births and consequently about 5–20,000 in-
fants per year are affected in Europe [1]. In regions with
lower level perinatal care it is even more common. HIE
affects about 1 million infants worldwide each year.
Up to now, the only established therapy to improve
outcome in infants with HIE is therapeutic hypothermia
[2, 3]. However, despite therapeutic hypothermia and
modern supportive neonatal intensive care, 45–50% of
the infants with moderate or severe HIE (i.e., 2500–10,
000 infants per year in Europe) still die or suffer from
long-term neurodevelopmental impairment (NDI) such
as cerebral palsy (CP), cognitive or behavioral problems
[2, 4]. Therefore, additional therapies, including pharma-
cotherapy, are investigated to further improve the neuro-
developmental outcome of infants with HIE.
One of the potential beneficial pharmacological inter-
ventions is allopurinol. Allopurinol is a xanthine oxidase
inhibitor, which reduces the production of oxygen radi-
cals, most importantly of superoxide [5]. Superoxide
radicals damage mitochondria resulting in secondary en-
ergy failure and apoptosis affecting neurons and glial
cells after reperfusion of hypoxic brain tissue, this is
called reperfusion injury [6, 7]. This reperfusion injury
leads to additional brain injury occurring in the hours
after birth and may affect much larger areas of brain
tissue than the area primarily affected during the senti-
nel event [7]. Superoxide production, which is reduced
by allopurinol, reaches its peak within 30 min after birth
and therefore early administration is important to
reduce reperfusion injury [8]. Furthermore, allopurinol,
especially in higher concentrations, possibly chelates
non-protein bound iron and scavenges the hydroxyl free
radicals [9, 10]. Allopurinol also prevents adenosine deg-
radation, which is an anti-excitatory neuromodulator
[11]. Thereby, allopurinol might reduce reperfusion
injury and improve outcome in neonates with HIE.
Several preclinical and three small clinical studies in
neonates with HIE suggested a possible neuroprotective
effect of allopurinol (recently reviewed in Annink et al.
[8]). In the first two studies of van Bel et al. and Benders
et al. allopurinol was administered within 4 h after birth.
Allopurinol improved neurodevelopmental outcome in
infants with moderate HIE, but not in severe HIE
[12–14]. Gunes et al. administered allopurinol for
three days and found improved outcome at one year
of age [15]. All three studies were conducted before
therapeutic hypothermia became standard of care, so
the effect of allopurinol in addition to therapeutic
hypothermia has not been investigated yet.
Based on the hypothesis that administration within
4 h after birth was too late to achieve full neuropro-
tective effect, allopurinol was administered antenatally
in case of suspected hypoxia in the antenatal allopur-
inol trial for reduction of birth asphyxia induced
brain damage (ALLO-trial) [16]. In girls, biomarkers
as S100B were reduced in the allopurinol group
compared to the placebo group. However, there was
substantial overtreatment on the one hand and on the
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other moderately and severely asphyxiated infants
were often missed [16].
Consequently, in this study on the effects of ALlopurinol
in addition to hypothermia treatment for hypoxic-
ischemic Brain Injury on Neurocognitive Outcome
(ALBINO), allopurinol will be administered intravenously
within 30 (max. 45) minutes after birth to optimize the
timing and inhibition of superoxide formation in
asphyxiated infants with evolving HIE.
Importantly, in all antenatal and neonatal studies in
HIE, no severe side-effects were seen [12, 13, 15–19].
Also, in other neonatal populations, such as preterm
infants and infants with congenital cardiac abnormal-
ities, no severe side effects have been reported follow-
ing (intravenous or oral) administration of allopurinol
[20–24]. In the ALLO-trial, 4.5% of the mothers who
received allopurinol had an irritation of the perivascu-
lar tissue, caused by the high pH of the allopurinol
solution, but this was reversible in all cases [16]. In
adults, a rare hypersensitivity reaction to allopurinol
has been described after daily administration for a
median of two to three weeks [25, 26]. An allopurinol
sensitivity reaction in neonates has never been re-
ported and is expected to be extremely unlikely.
Methods/design
Trial objectives
The main objective of the ALBINO trial is to evaluate
the effect of early postnatal allopurinol administered in
addition to standard of care (including therapeutic
hypothermia if indicated) on the incidence of death and
severe NDI at 24 months of age in newborns with HIE.
Secondly, safety of early postnatal intravenous allopur-
inol will be evaluated, as well as the pharmacokinetic
profile of intravenous allopurinol and the short-term effect
of early allopurinol on brain injury assessed by magnetic
resonance imaging (MRI) of the brain, cerebral ultrasound,
heart function assessed by echocardiography, electro-
encephalography (EEG), and biochemical biomarkers.
Trial design
The ALBINO trial is a European double-blinded random-
ized placebo-controlled parallel group multicenter trial for
superiority of allopurinol versus placebo (mannitol) in
addition to therapeutic hypothermia where indicated (Phase
III). More than 60 hospitals in ten countries will participate
in this study, and ALBINO may expand to additional sites
in further countries, after appropriate approvals have been
obtained from ethics committees and authorities.
Population
Term and near-term infants (≥36 weeks) with severe
perinatal asphyxia and potentially evolving encephalop-
athy can be included in the ALBINO trial:
Inclusion criteria
Infants must meet at least one of the following five
criteria of severe perinatal asphyxia: 1) umbilical or post-
natal blood gas within 30 min after birth with a pH < 7.0
or 2) with a base deficit ≥16 mmol/l; 3) need for ongoing
cardiac massage at/beyond 5min postnatally; 4) need for
adrenalin administration during resuscitation and/or 5)
Apgar score ≤ 5 at 10 min after birth.
Further, the infant must meet two out of the following
four criteria for potentially evolving encephalopathy to
participate in the study: 1) altered state of consciousness
(reduced or absent response to stimulation or hyperex-
citability); 2) severe muscular hypotonia or hypertonia;
3) absent or insufficient spontaneous respiration (i.e.
gasping only) with need for respiratory support at 10
min postnatally and/or 4) abnormal primitive reflexes
(absent suck/gag/ corneal/Moro reflex) or abnormal
movements (i.e. potential clinical correlates of seizure
activity).
Exclusion criteria
Infants will be excluded if the gestational age is below
36 weeks, birth weight is below 2500 g, in the presence
of severe congenital malformations or syndromes requir-
ing neonatal surgery or affecting long-term outcome.
Furthermore, infants will be excluded if their postnatal
age is > 30 min at the end of the screening phase, the
neonate is considered “moribund” or “non-viable”, there
is a decision of ‘comfort care only’ before study drug
administration or if parents decline study participation.
Randomization and allocation concealment
Randomization will be performed with randomization
software (Randlist Version 1.2) in blocks of four and
stratified per center.
Randomization will be performed by allocation of the
next consecutive study medication box (including first
and second vial of study medication and two vials with
sterile water for reconstitution) to an infant.
Study intervention
Infants included in the ALBINO trial will receive either
allopurinol or placebo (mannitol). Study medication will
be administered by intravenous infusion in one or two
doses (see Fig. 1). The first dose (20 mg/kg body mass
reconstituted in 2.0 ml/kg sterile water for infusion) will
be given as soon as possible after birth. The start of infu-
sion of study medication should preferably be within 30
min after birth, but no later than 45min after birth.
The second dose (10 mg/kg body mass reconstituted
in 1.0 ml/kg sterile water for infusion) will be adminis-
tered 12 h after the first dose. This second dose will only
be administered to infants treated with therapeutic
hypothermia. Infants who recover quickly and do not
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qualify for and hence do not undergo hypothermia will
not receive a second dose.
Placebo (mannitol) will be given in the same dose,
volume and intervals as allopurinol.
Concomitant interventions and medication
Any concomitant medication that is medically necessary
for the patients will be allowed in the study, except
open-label allopurinol in any dosage and any application
mode.
Where indicated according to respective national
standards or treatment protocols, hypothermia treat-
ment (whole body cooling to 33.5 °C for 72 h) should
be started as soon as possible according to local
protocols [3, 27].
Primary outcome
The primary endpoint will be death or severe NDI
versus survival without severe NDI at the age of two
years. Severe NDI is hereby defined as any of the follow-
ing: cognitive or language delay defined as a cognitive-
composite-score or a language-composite-score on the
Bayley Scales of Infant and Toddler Development (3rd
edition) < 85 and/or cerebral palsy (CP) according to the
Surveillance of Cerebral Palsy in Europe (SCPE) criteria.
Secondary and further outcomes
The primary endpoint will be reconstituted as dichoto-
mized composite secondary endpoint (survival without
NDI versus Death or language-composite-score < 85 or
cognitive-composite-score < 85 or CP present). Further-
more, the incidences of death and CP and the composite
scores derived from the Bayley test (continuous and dichot-
omized) as well as the Gross Motor Function Classification
Score will be analyzed as secondary outcome variables.
Further important secondary outcome parameters are
brain injury assessed by MRI of the brain, cerebral ultra-
sound, amplitude-integrated EEG, full scale multichan-
nel EEG, heart function assessed by echocardiography,
concentrations of peroxidation products and S100B
which are markers for brain injury in the blood. Further-
more, pharmacokinetics of allopurinol will be investi-
gated in 48 to 52 patients. Finally, the opinions of
parents experiencing two different consent procedures
will be evaluated.
Parental perspectives
Following study participation, parents will be approached
again and asked for their opinion on and satisfaction with
the consent procedure to inform future investigators in
the field of HIE therapy.
Ethical Considerations
Because allopurinol has to be administered as early as
possible after birth to reduce formation of oxygen radi-
cals during reperfusion and because the emergency situ-
ation of perinatal asphyxia is very stressful for the
parents, the usual procedure of provision of comprehen-
sive oral and written information, time for consideration
and full written informed parental consent before study
entry is not feasible in the setting of ALBINO. This
problem and the various alternative approaches
(antenatal consent, short information and oral consent
and later full information and written confirmation,
Fig. 1 Study interventions in ALBINO
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waiver of consent for 1st dose and deferred information
and consent), have been discussed with external experts
on perinatal HIE as well as medical ethicists and a
balance between the need to inform the parents and the
feasibility of the study was sought in collaboration with
the relevant ethics committees in each participating
country.
Community Engagement
Information material, such as posters and flyers, that
provides short information for parents, will be available
in prenatal clinics and delivery areas and will direct
interested parents to the study home page (www.albino-
study.eu).The homepage will grant access to nationally
approved full parent information material. A press re-
lease will inform the community around study sites
about the ALBINO study.
Parents, who do not want to participate in the
ALBINO-trial, will have the option to deny participation
even before delivery verbally or on a ‘declaration of in-
tent’-form printed on the flyers informing about the
study. This can be completed and kept in the maternal
health passport to inform the staff in the delivery room.
Form of Consent
According to the relevant ethics committee’s decisions,
either a deferred consent or an initial short oral consent
approach will be used for obtaining parental consent.
The deferred consent procedure has previously been
used in emergency research in adults and is in compli-
ance with §30 of the Declaration of Helsinki (Fortaleza
2013 [28]). In the case that a child fulfills the inclusion
criteria and meets no exclusion criterion, physicians will
administer the first dose of study medication in the de-
livery room without prior consent (i.e., a ‘consent waiver’
was granted for the 1st dose of study medication).
Parents will receive detailed information later and will
be asked for written informed consent for continued
participation in the study (as soon as possible, at the lat-
est before the 2nd dose of study medication if indicated).
The deferred consent procedure has been approved in
Austria, Belgium, Estonia, Finland and Norway.
In Germany, the Netherlands, Italy, Switzerland and
Spain, the ethical committees did not agree on the de-
ferred consent procedure, so in these countries the short
oral consent procedure will apply: short oral information
(duration < 5min) on the indication and the potential
benefits and risks of the study medication must be pro-
vided to at least one parent and oral (or written) consent
of this parent must be obtained before the 1st dose of
study medication can be administered. Again, both
parents will receive more detailed information and will
be asked for full written consent as soon as possible and
at the latest before the 2nd dose of study medication will
be administered (if indicated).
Statistical analysis
Sample size, power and study duration
The primary assessment for efficacy will compare the
proportions of infants surviving without severe NDI
versus those of infants who died or survived with severe
NDI at the age of two years.
Based on the above referenced (preliminary) clinical
studies from the pre-therapeutic hypothermia era and
clinical studies on hypothermic treatment, it is estimated
that the combined incidence of death and severe NDI in
the control group will be 37 and 27% in the allopurinol
group. Therefore, we calculated with a two-sided X2-test
(alpha = 0.05, power 80%) a sample size of 682 infants
(341 per treatment group) in which the primary out-
come should be ascertained. Assuming a drop-out rate
of 10% for loss to follow-up, a total of 760 infants need
to be enrolled. And assuming that 10% of the parents
will refuse participation after the initial dose of the study
drug, 846 infants have to be randomized (see Fig. 2).
We estimate a recruitment of about 35 patients per
month in approximately 70 study centers (the recruitment
of additional study sites is ongoing) and therefore recruit-
ment will last 24months.
Data analysis
All statistical analyses will be described in detail in a
statistical analysis plan completed before closure of the
database.
Monitoring safety
An independent Data Monitoring Committee (DMC)
will monitor the participants’ well-being and the overall
risk/benefit-ratio of the study. National monitors will
monitor the accuracy and completeness of the data and
the safety issues such as the presence of serious adverse
events.
Regulatory aspects
Trial sponsor
Sponsor of the ALBINO-trial is the University Hospital
Tuebingen, Geissweg 3, 72076 Tuebingen, Germany.
Contact is available under albino@med.uni-tuebingen.de.
Orphan Drug Designation
The Committee for Orphan Medicinal Products
(COMP) has given a positive advice to ACE Pharmaceu-
ticals for the orphan drug designation for allopurinol
sodium for treatment of perinatal asphyxia (EU/3/15/
1493) and an Orphan Drug Designation has been
granted by the European Medicines Agency. The
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public summary is available at: https://www.ema.eur-
opa.eu/documents/ orphan-designation/eu/3/15/1493-
public-summary-opinion-orphan-designation-allopur-
inol-sodium-treatment-perinatal-asphyxia_en.pdf.
Scientific Advice from the European Medicines Agency
In November 2015, ACE Pharmaceuticals has requested
Scientific Advice and Protocol Assistance from the
European Medicines Agency, including questions specif-
ically related to the study protocol and the intended
procedure of deferred consent. Written scientific advice
was received in May 2016 and after careful consideration
by the Steering Committee, the relevant issues were
subsequently incorporated into the study protocol.
Medical ethics committees
At the time of publication, the relevant ethics commit-
tees in ten European countries approved the study with
either the short oral consent procedure or the deferred
consent procedure. Applications for approvals are
currently underway in two additional countries.
National Regulatory/Competent Authorities
At the time of publication, eleven European National
Regulatory/Competent Authorities approved the study.
Application for approval is currently underway in one
additional country.
Discussion
ALBINO is a randomized controlled trial investigating
the safety and efficacy of allopurinol in (near-) term in-
fants with HIE.
A decision was made for a large phase III trial for
efficacy and safety because preliminary clinical data from
postnatal and prenatal allopurinol trials already sug-
gested a reduction in brain injury by allopurinol without
apparent adverse effects. Another small proof-of-
principle or dose seeking study would have added little
with respect to safety and clinically relevant outcomes.
Survival without NDI was selected as the primary
endpoint of this study, because this outcome parameter
is most meaningful to the children and their families.
The calculated starting dose was based on previous
studies: the doses used in the first studies with
allopurinol in neonates undergoing extracorporeal
1200 infants with umbilical 
arterial pH<7.0 or need for 
resuscitation to be screened
846 infants with HIE
to be randomised 
as soon as possible 
but before 30min after birth 
at the latest
423 to receive 
1st dose of allopurinol (20mg/kg) i.v. 
423 to receive 
1st dose of placebo i.v. 
43 (10%) lost 
because 
parents refuse 
participation 
(included in 
safety analysis 
if parents 
consent to this)
380 (90%) 
infants remaining 
in the study
43 (10%) lost 
because 
parents refuse 
participation 
(included in 
safety analysis if 
parents consent 
to this)
380 (90%) 
infants 
remaining in the 
study
76 (20%) 
anticipated to 
recover quickly
304 (80%) 
anticipated to 
have moderate 
(52%) or severe 
(28%) HIE
76 (20%) 
anticipated to 
recover quickly
304 (80%) 
anticipated to 
have moderate 
(52%) or severe 
(28%) HIE
No hypothermia 
treatment and 
no further dose 
of allopurinol.
Hypothermia 
treatment and 2nd
dose allopurinol 
(10mg/kg) i.v.
No hypothermia 
treatment and 
no further dose 
of placebo
Hypothermia 
treatment and 2nd
dose of placebo 
i.v.
Uniform outcome assessment 
with MRI at 4-6 days after birth and 
neurodevelopmental follow-up
at 24 months corrected age 
and ascertainment of primary outcome 
in
at least 342 infants randomised to 
verum
(allowing for 10% lost to follow-up)
Uniform outcome assessment 
with MRI at 4-6 days after birth and 
neurodevelopmental follow-up
at 24 months corrected age and 
ascertainment of primary outcome in
at least 342 infants randomised to 
placebo
(allowing for 10% lost to follow-up)
Fig. 2 Anticipated Trial Flow
Maiwald et al. BMC Pediatrics          (2019) 19:210 Page 6 of 10
membrane oxygenation and in neonates diagnosed with
hypoplastic left heart syndrome (10 and 30mg/kg birth
weight respectively) gave 100% xanthine-oxidase inhibition
[21, 23]. Higher concentrations may be needed for the
iron chelating and reactive oxygen scavenging effect
of allopurinol. Even with higher doses (up to 40 mg/
kg birth weight per day for 3 days) no adverse effects
were seen, with special attention to skin rashes and
leukopenia [15].
A significant beneficial effect of allopurinol in moder-
ately asphyxiated neonates has been found on long-term
(4–5 years) neurodevelopmental outcome by Kaandorp
et al. (2012), which was a meta-analyses of the study
from van Bel et al. (1998) and Benders et al. (2006)
[12, 13]. These latter trials administered 2 times 20
mg/kg birth weight allopurinol with 12 h interval. The
doses of the ALBINO trial are based on these three
studies. However, pharmacokinetics of allopurinol
during hypothermia have not yet been determined in
neonates with HIE. The second dose in the ALBINO
study (only during hypothermia) is adjusted for the
hypothermia treatment which may possibly slow-down
allopurinol and oxypurinol metabolism and elimin-
ation. In the latter case this would lead to higher cir-
culating concentrations of allopurinol and,
respectively, oxypurinol.
In previous studies the plasma concentrations of
allopurinol were often supra-therapeutic without any
side effect [19, 29]. These supra-therapeutic levels seem
to be important for the direct scavenging of hydroxyl
and free iron by allopurinol. However, to ensure that in
addition to therapeutic hypothermia plasma concentra-
tions are not lower than in the earlier clinical trials indi-
cating efficacy, blood sampling for pharmacokinetic
analyses will be performed in 48 to 52 infants (in
selected centers) recruited during the first year of the
study and may lead to adaptation of doses.
Mannitol is used as placebo, since its freeze-dried
white powder and the reconstituted solution, have the
same visual aspects and volume as the freeze-dried so-
dium salt of allopurinol and its reconstitution solution
(10 ml of a colorless, clear solution in a 20ml vial). The
dosage of mannitol is 50 times lower than the dose of
mannitol used for neuroprotection [30], and a normal
daily dose of intravenous paracetamol will include more
mannitol as supporting agent than the dose adminis-
tered in ALBINO (i.e. 100 ml solution for injection
contains 1000mg acetaminophen and 3670-3850 mg
mannitol [31, 32]. For each single dose of 12.5 mg/kg
paracetamol i.v. [33], 45.9–48.1 mg/kg of Mannitol are
concomitantly administered).
Inclusion and exclusion criteria were selected to
recruit a patient population similar to the TOBY trial of
whole body cooling [3], but took into account that the
assessment for eligibility has to be done much earlier,
i.e., within 30 min after birth.
The ALBINO study group extensively discussed the
various ethical implications of need for additional treat-
ment for HIE, need to administer allopurinol very early
for best efficacy, need for parental consent to ensure
patient autonomy and burden to the parents in the
emergency situation of perinatal HIE.
The European Foundation for the Care of Newborn
Infants (EFCNI), which is composed of parents, health-
care experts, scientists and politicians, has been asked
for advice. The EFCNI endorsed the conduct of the
ALBINO trial in a letter of support in September 2016.
Because perinatal HIE occurs rarely and unpredictably
and because of the need for very early administration of
allopurinol, the EFCNI agreed with the approach of
deferred consent.
Furthermore, independent ethics experts provided ad-
vice. Whereas all experts agreed that regular informed
consent by the parents, which includes appropriate time
for reflection and further questions is not feasible before
administration of the 1st dose of study medication in the
context of ALBINO due to the unpredictable emergency
situation. Opinions within the group as well as among
external experts ranged from ‘deferred consent is un-
acceptable’ to ‘deferred consent is justified and the better
option’, so that the decision was left to the national lead-
ing ethics committees in each country.
Currently, we are conducting a survey among
parents-to-be and parents of infants with a history of
HIE to better understand how parents might feel
about deferred versus short oral consent. An add-
itional survey will follow parents of infants enrolled
in the ALBINO study to capture their satisfaction
with the various approaches and to inform future
trials in similar situations.
In conclusion, infants with HIE still suffer from death
and long-term NDI despite improved standards of care in-
cluding therapeutic hypothermia. The neurodevelopmental
outcome of infants with HIE should be further improved
with additional neuroprotective interventions. The aim of
the ALBINO trial is to investigate the neuroprotective effect
of very early allopurinol within 45min after birth aiming to
reduce the formation of the toxic superoxide and subse-
quent secondary energy failure and apoptosis.
Trial status
Protocol version 5: 19. December 2017. Recruitment has
started in April 2018 and is expected to be finalized in
April 2020. The last patient out (after follow-up) will
then be expected in April 2022.
Abbreviations
ALLO-trial: Antenatal allopurinol trial for reduction of birth asphyxia induced
brain damage; CP: Cerebral Palsy; COMP: Committee for Orphan Medicinal
Maiwald et al. BMC Pediatrics          (2019) 19:210 Page 7 of 10
Products; DMC: Data Monitoring Committee; ALBINO: Effect of Allopurinol in
addition to hypothermia for hypoxic-ischemic brain injury on neurocognitive
outcome; EEG: Electro-encephalography; EFCNI: European Foundation for the
Care of Newborn Infants; HIE: Hypoxic-ischemic Encephalopathy;
MRI: Magnetic Resonance Imaging; NDI: Neurodevelopmental Impairment;
SCPE: Surveillance of Cerebral Palsy in Europe; TOBY: Total Body Hypothermia
for Neonatal Encephalopathy Trial
Acknowledgements
The ALBINO consortium is indebted to Silke Mader and Nicole Thiele from
the European Foundation for the Care of Newborn Infants (EFCNI) who
granted a letter of support for the ALBINO study after careful evaluation of
the various arguments.
We would also like to thank the members of the Data Monitoring Committee:
Michael Weindling (University of Liverpool), Sandra Juul (University of
Washington), Steven Miller (Hospital for Sick Children Toronto), Edwin Spaans
(Erasmus University Rotterdam) and Josef Högel (University of Ulm), and the
members of the ALBINO External Advisory Board: Seetha Shankaran,(Wayne
State University Detroit) and Neil Marlow (University College London).
ALBINO study group:
Coordinating Investigators: Axel R. Franz (University Hospital Tuebingen,
Germany; corresponding and senior author) and Mario Rüdiger (University
Hospital C.G. Carus - Medizinische Fakultät der TU Dresden, Germany).
Beneficiaries / National Coordinators: Axel R. Franz and Christian F. Poets
(Tuebingen, Germany), Mario Rüdiger (Dresden, Germany), Manon Benders and
Frank van Bel (Utrecht, the Netherlands), Karel Allegaert and Gunnar Naulaers
(Leuven, Belgium), Dirk Bassler (Zurich, Switzerland), Katrin Klebermaß-Schrehof
(Vienna, Austria), Maximo Vento (Valencia, Spain), Hercilia Guimarães (Porto,
Portugal), Tom Stiris (Oslo, Norway), Luigi Cattarossi (Udine, Italy), Marjo
Metsäranta (Helsinki, Finland), Sampsa Vanhatalo (Helsinki, Finland), Jan Mazela
(Poznan, Poland), Tuuli Metsvaht (Tartu, Estonia), Cees K.W. van Veldhuizen
(Zeewolde, the Netherlands).
Data Management, Biometry, Monitoring, and Study Coordination, all at the
Center for Pediatric Clinical Studies, University Hospital Tuebingen: Corinna Engel,
Christian A. Maiwald, Gabriele von Oldershausen, Iris Bergmann, Monika Weiss,
Caroline J. B. R. Wichera, Andreas Eichhorn, Michael Raubuch, Birgit Schuler.
Industry Partner: Cees K.W. van Veldhuizen, Bas Laméris, Yannique Jacobs,
Roselinda van der Vlught-Meijer (all ACE Pharmaceuticals BV, Zeewolde, the
Netherlands).
Recruiting Hospitals and Local Principal Investigators:
Austria: Medizinische Universitaet Wien Katrin Klebermaß-Schrehof, Medizinische
Universität Graz Gerhard Pichler, Tirol Kliniken - Universitätskliniken Innsbruck
Elke Griesmaier, Uniklinikum Salzburg Johannes Brandner.
Belgium: University Hospitals Leuven Gunnar Naulaers, CHU St. Pierre University
Hospital Brüssel Marie Tackoen and Ruth Reibel, CHR - Grand Hopital de Charleroi
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Hospital Santa Maria - Centro Hospitalar Universitario de Lisboa Norte André
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